BioXcel Therapeutics, Inc.
BTAI
$2.03
$0.126.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -66.96% | -63.88% | 5.47% | 64.20% | 83.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -66.96% | -63.88% | 5.47% | 64.20% | 83.25% |
| Cost of Revenue | -52.42% | 55.19% | 56.01% | 70.02% | 264.39% |
| Gross Profit | -184.80% | -221.26% | -153.30% | 2.52% | -63.56% |
| SG&A Expenses | -48.04% | -59.26% | -63.16% | -58.65% | -57.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.07% | -52.32% | -63.05% | -60.31% | -62.11% |
| Operating Income | 32.03% | 52.06% | 63.91% | 61.34% | 63.01% |
| Income Before Tax | 3.92% | 52.75% | 73.82% | 66.71% | 66.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.92% | 52.75% | 73.82% | 66.71% | 66.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.92% | 52.75% | 73.82% | 66.71% | 66.45% |
| EBIT | 32.03% | 52.06% | 63.91% | 61.34% | 63.01% |
| EBITDA | 32.15% | 52.21% | 64.05% | 61.45% | 63.10% |
| EPS Basic | 71.84% | 77.72% | 83.69% | 73.70% | 70.75% |
| Normalized Basic EPS | 71.13% | 77.74% | 84.39% | 74.06% | 70.97% |
| EPS Diluted | 71.84% | 77.72% | 83.69% | 73.70% | 70.75% |
| Normalized Diluted EPS | 71.13% | 77.74% | 84.39% | 74.06% | 70.97% |
| Average Basic Shares Outstanding | 234.79% | 126.31% | 75.64% | 39.14% | 24.16% |
| Average Diluted Shares Outstanding | 234.79% | 126.31% | 75.64% | 39.14% | 24.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |